A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
Completed · Phase 1
Conditions studied: Small Cell Lung Carcinoma
In brief
The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 in participants with varying degrees of hepatic impairment.
Key facts
- Study ID
- NCT05329623
- Run by
- Novartis Pharmaceuticals
- People needed
- 33
- Starts
- 2022-05-03
- Expected to finish
- 2024-04-07
- Last updated by the study team
- 2025-10-10
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orlando Clinical Research Center — Orlando, Florida, United States
- Texas Liver Institute — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.